Quick answer
Cagrilintide is a synthetic, long-acting analog of amylin (about 4,409 Da) carrying anti-aggregation substitutions, a disulfide ring and a C20 fatty diacid, studied as a research tool for amylin-receptor signaling.
- Structure: acylated amylin analog with a disulfide ring and albumin-binding lipid side chain
- Mechanism: agonist of calcitonin receptor/RAMP (AMY1-3) complexes, distinct from incretin receptors
- Evidence: receptor-expressing cells and rodent models; often paired with GLP-1 agonists
- Handling: amphiphilic, so swirl gently and aliquot; concentration = mg ÷ mL via the calculator
- Research use: For laboratory research use only; not for human consumption.
What cagrilintide is
For laboratory research use only; not for human consumption.
Cagrilintide is a synthetic, long-acting analog of amylin, a pancreatic peptide hormone co-secreted with insulin. It is studied as a research tool for amylin-receptor signaling and is of particular interest in metabolic research, where it is routinely examined alongside incretin-pathway compounds to compare complementary signals. Its theoretical average mass is approximately 4,409 Da, which includes the peptide backbone, a linker and a fatty diacid.
Three engineered features distinguish it from the native hormone: amino-acid substitutions that suppress aggregation, an intramolecular disulfide ring retained from the amylin architecture, and a lipid (fatty diacid) side chain that promotes reversible albumin binding. Together they convert an aggregation-prone, short-lived hormone into a reagent suitable for sustained in-vitro and animal-model work.
| Property | Cagrilintide |
|---|---|
| Class | Acylated amylin analog |
| Parent hormone | Human amylin (37 residues, Cys2-Cys7 disulfide, amidated C-terminus) |
| Approximate molecular weight | About 4,409 Da (theoretical average) |
| Key modifications | Anti-aggregation substitutions, disulfide ring, C20 fatty diacid via a linker |
| Receptor system studied | Calcitonin receptor and calcitonin receptor/RAMP (amylin receptor) complexes |
| Supplied form | Lyophilized powder |
| Typical research setting | Cell-based receptor assays and rodent metabolic models |
Cagrilintide is most often discussed in two contexts: against the earlier amylin analog pramlintide, covered in cagrilintide vs. pramlintide, and in combination with GLP-1-pathway agonists, covered in cagrilintide and semaglutide combination research. The catalog entry is the cagrilintide research vial.
Discovery and history
Cagrilintide is a comparatively recent entry in peptide research. It arrived amid the surge of interest in metabolic peptides that also elevated the GLP-1 receptor agonists, and its history is tied to that wave.
The limits of native amylin
Amylin had long been recognized as an interesting metabolic signal, but human amylin aggregates into amyloid fibrils in aqueous solution and is short-lived. Both properties limit its use as a stable reagent, since aggregation changes the effective concentration during an experiment. Overcoming those liabilities was the central design problem.
Reengineering the scaffold
The development path depended on prior understanding of amylin-family structure and receptor pharmacology. Once researchers could preserve receptor-recognized features while replacing aggregation-prone regions, the scaffold became tractable. Fatty-acid conjugation then supplied a separate solution to persistence. Cagrilintide therefore represents a convergence of hormone biology, sequence engineering and long-acting peptide chemistry, and illustrates how established biology can be revisited with modern stabilization techniques rather than inventing a new scaffold. The resulting features are detailed in cagrilintide chemical structure and synthesis.
Part of a combination narrative
Much of cagrilintide's prominence comes from its study alongside GLP-1-class peptides, reflecting a broader trend toward pairing complementary metabolic signals. The distinct pathways involved are outlined in incretin receptors explained.
Keeping research eras distinct
The history of native amylin, earlier analogs and cagrilintide should not be collapsed into one evidence base. Each molecule has different sequence features and experimental properties, and observations from studies pairing an amylin analog with an incretin-pathway tool should be distinguished from data on the isolated analog. Analytical progress was part of the story too: modern chromatography and mass spectrometry made it possible to verify long modified sequences, lipid attachment and cyclic features with confidence, so that several engineered properties could be confirmed simultaneously. Further chronology is in cagrilintide discovery and history.
Chemical structure and synthesis
Each structural feature of cagrilintide addresses a specific limitation of amylin as a research molecule.
| Feature | Purpose | Analytical consequence |
|---|---|---|
| Anti-aggregation substitutions | Improve solubility and resist fibril formation seen with native amylin | Sequence identity confirmed by mass |
| Intramolecular disulfide ring | Fixes the conformation needed to engage the receptor system; hallmark of the amylin/calcitonin family | Oxidized form differs in mass and retention from reduced or mispaired species |
| C20 fatty diacid with short linker | Promotes reversible serum albumin binding and slows clearance in model systems | Lipid adds mass and strongly alters HPLC retention |
| C-terminal amidation (amylin architecture) | Retains the native-like terminal chemistry | Part of the expected mass |
The amylin scaffold
Native amylin is 37 residues long with a disulfide between Cys2 and Cys7 and an amidated C-terminus. Cagrilintide preserves the recognizable architecture while altering the segments responsible for instability. General principles of how sequence drives properties are covered in understanding amino acid sequences.
Disulfide ring and acylation
The internal disulfide links two cysteines to form a small ring near one end of the chain, helping fix the conformation the peptide uses to engage its receptor. The lipid side chain is attached near the N-terminus through a short linker. This strategy of reversible albumin binding is a common theme in modern metabolic-peptide engineering, comparable to the stabilization approach used for CJC-1295 with DAC.
Synthesis and purification
Assembly uses solid-phase peptide synthesis with controlled disulfide formation, followed by purification and freeze-drying (what is lyophilization). Long, acylated, disulfide-containing peptides present several challenges at once. Side-chain protecting groups must survive chain elongation yet be removable without damaging the product; the lipid attachment must occur at the intended site; and oxidation must yield the correct intramolecular bridge rather than intermolecular species. Purification separates deletion sequences, acylation variants and mispaired or aggregated material.
What a quality record should establish
A useful analytical package distinguishes identity from purity. Expected mass supports sequence and modification identity; chromatographic data estimate the relative abundance of the main component; additional characterization may support correct disulfide formation. Because acylation and oxidation both change mass and retention, records should describe the intended molecular form rather than a generic peptide name. The full chemistry write-up is at cagrilintide chemical structure and synthesis.
Mechanism of action
Cagrilintide's proposed mechanism centers on the amylin-receptor system. Amylin receptors are not a single protein but complexes formed when the calcitonin receptor associates with one of three receptor-activity-modifying proteins (RAMPs), which tune the complex toward amylin recognition. The three RAMPs give three receptor subtypes, usually written AMY1, AMY2 and AMY3. Cagrilintide is described as a non-selective agonist that also activates the calcitonin receptor on its own, so cell-based work typically compares potency across all four receptor configurations using cAMP accumulation as the readout.
Receptor engagement
By mimicking amylin, cagrilintide engages calcitonin-receptor/RAMP complexes and activates the associated G-protein signaling studied in metabolic model systems. Its long-acting design sustains this engagement relative to native amylin. In rodent work, attention has focused on hindbrain regions such as the area postrema, where amylin-responsive neurons are concentrated.
Complementary to incretins
Amylin signaling is mechanistically distinct from the receptors described in GLP-1, GIP and glucagon explained. This separation is why cagrilintide is studied in parallel with agonists such as semaglutide: combining pathways lets researchers assign each readout to a system.
| Design question | Why it matters | Practical approach |
|---|---|---|
| Which receptor configuration drives the response? | RAMP partners alter ligand recognition and signaling of the calcitonin receptor | Receptor profiling, matched positive controls, selective pathway interference |
| Is a long signal stronger or just longer? | Slow clearance, persistent occupancy or trafficking changes can prolong a signal | Time-course experiments separating peak response from duration |
| Does protein binding change apparent activity? | Albumin lowers the free fraction of a lipidated peptide | Run albumin-containing and albumin-free conditions side by side |
| Is the response desensitizing? | Sustained agonist exposure can alter surface receptor abundance | Measure receptor localization and recovery of response |
Interpreting results
A prolonged signal does not necessarily mean stronger intrinsic activation at every moment. Receptor desensitization is another possible contributor to time-dependent data, so later measurements may not mirror the initial signal. A model's receptor and RAMP expression affects interpretation, and selective interference helps establish that a response is mediated by an amylin-receptor complex rather than by an unrelated stress or off-target process. In-vitro concentrations are set by assay design and readouts describe controlled model behavior only. The dedicated article is cagrilintide mechanism of action.
Preclinical research findings
Preclinical work on cagrilintide centers on its identity as an amylin-receptor-targeting analog engineered for extended duration, which makes the record as much a story about peptide engineering as about receptor pharmacology. Published work on amylin analogs typically moves through a sequence of systems, each answering a different question.
| Model system | Endpoints | What it tells you |
|---|---|---|
| Receptor-expressing cell lines (defined calcitonin receptor/RAMP combinations) | cAMP accumulation, receptor-binding competition | Potency and selectivity across calcitonin and amylin receptor subtypes |
| Fibrillation assays | Thioflavin-T fluorescence over time | Whether the analog resists the aggregation of native amylin |
| Rodent pharmacokinetics | Plasma exposure and clearance versus shorter-acting analogs | How far lipidation extends exposure |
| Larger-species pharmacokinetics | Time-course exposure over several days | Persistence of the protein-bound reservoir |
| Diet-induced obese rodents | Food intake, body composition, energy-expenditure readouts | Pathway behavior in an energy-balance model |
| Combination arms with a GLP-1 receptor agonist | Single-agent and combined readouts | Whether the two pathways act independently, additively or interactively |
Extended-duration design
The key change is lipidation: a C20 fatty diacid attached near the N-terminus through a short linker promotes non-covalent association with albumin, so the peptide circulates as a protein-bound reservoir in animal models. Backbone substitutions reduce aggregation. Pharmacokinetic studies in rodents and larger species have been used to quantify how far these modifications extend exposure compared with unmodified amylin analogs.
Metabolic-signaling context
Because amylin and incretin pathways are frequently studied together, cagrilintide work is often framed beside GLP-1-pathway compounds. In rodent studies this usually takes the form of single-agent arms and a combination arm, with food intake and body composition as readouts. The comparative literature is surveyed in the semaglutide, tirzepatide, retatrutide and cagrilintide comparison.
Potency versus persistence
A recurring point is that persistence and potency are different properties. Albumin binding lowers the free fraction of a lipidated peptide, so apparent potency in a serum-albumin-containing assay can be much lower than in an albumin-free buffer even though the molecule is unchanged. Careful studies report assay protein content and compare analogs under matched conditions before drawing conclusions about receptor activity.
Limits of the evidence
Rodent amylin and calcitonin receptors differ from their human counterparts in pharmacology, albumin binding varies by species, and feeding paradigms are sensitive to housing, diet and handling. Useful reports state species, strain, diet, housing temperature and vehicle, because each can shift an energy-balance readout on its own. Results from one model should not be generalized without those caveats. The summary article is cagrilintide preclinical research.
Handling, reconstitution and storage
Cagrilintide is supplied as a lyophilized powder. Lipidation makes the molecule amphiphilic, so it has a stronger tendency than a plain peptide to self-associate and to adsorb to container surfaces. Slow addition of diluent, gentle swirling and low-binding labware for dilute solutions are the usual controls. This is laboratory handling information only; the detailed article is cagrilintide reconstitution and storage, and the generic method is in the lyophilized-peptide reconstitution guide. A worked example of the same technique with another lipidated peptide is how to reconstitute retatrutide step by step.
Preparing a stock solution
- Let the vial reach room temperature before opening; use sterile technique.
- Add bacteriostatic water slowly down the inside wall of the vial, not onto the cake.
- Dissolve by swirling. Do not vortex or shake, since amphiphilic peptides foam and can aggregate at air-liquid interfaces.
- Label with concentration and date.
Concentration is peptide mass divided by diluent volume (mg ÷ mL). The reconstitution calculator does the arithmetic for any vial.
| Vial mass | Diluent added | Resulting concentration |
|---|---|---|
| 5 mg | 1 mL | 5 mg/mL |
| 5 mg | 2 mL | 2.5 mg/mL |
| 10 mg | 2 mL | 5 mg/mL |
| 10 mg | 4 mL | 2.5 mg/mL |
These are arithmetic examples for stock planning only. Confirm the labeled mass of the vial in hand.
Storage
The lyophilized powder is the most stable form and should be kept cold, dry and away from light. The fatty-acid chain increases sensitivity to freeze-thaw cycling and to concentration-dependent aggregation, so storing small aliquots instead of a single large stock is the common control. General cold-chain principles are in storing research peptides. Lipidated peptides can adsorb to plastic and glass at low concentrations, so low-binding tubes and consistent diluents help keep nominal and actual concentrations aligned.
Purity, COA and quality
For cagrilintide, mass spectrometry is especially informative because it confirms that both the acyl chain and the disulfide are present; HPLC then estimates how much of the sample is the intended molecular form. Acylation variants and mispaired disulfide species can differ from the target by small mass or retention shifts, so a bare purity percentage is not enough.
| Test | Question answered | What to check for cagrilintide |
|---|---|---|
| Reversed-phase HPLC | What fraction is the main component? | Dominant peak with stated purity and an actual chromatogram |
| Mass spectrometry | Is the full modified molecule present? | Observed mass consistent with about 4,409 Da including linker and diacid |
| Lot traceability | Does the document match the vial? | Lot number identical on vial and certificate |
| Notebook record | Can another lab repeat the work? | Lot, storage conditions and reconstitution date recorded with the data |
Certificates are published on the COA page. Learn to read them in how to read a COA and understanding HPLC purity. Compound-specific detail is in cagrilintide purity testing; sourcing considerations are in where to buy cagrilintide for research, and the catalog entry is the cagrilintide product page.
Related compounds and comparisons
Cagrilintide is usually placed in one of two comparison sets: other amylin-pathway molecules, and incretin-pathway compounds studied in parallel. The table is about experimental role rather than relative performance.
| Compound | Pathway | Relationship to cagrilintide | Read more |
|---|---|---|---|
| Pramlintide | Amylin receptors | Earlier amylin analog; different sequence and properties | Cagrilintide vs. pramlintide |
| Semaglutide | GLP-1 receptor | Incretin comparator studied alongside; distinct receptor system | Semaglutide overview |
| Tirzepatide | GIP and GLP-1 receptors | Dual incretin agonist; separate from amylin signaling | Tirzepatide in metabolic research |
| Retatrutide | GIP, GLP-1 and glucagon receptors | Triple agonist; also lipidated | Retatrutide research FAQ |
| Combination research | Amylin plus GLP-1 | Pairing arms to separate pathway contributions | Cagrilintide and semaglutide combination research |
Native amylin, earlier analogs and cagrilintide are different molecules. Results obtained with native amylin cannot be transferred automatically to the analog, or the reverse, because sequence changes and acylation alter stability, protein binding and experimental exposure. Conclusions should state the molecular form actually tested. Study design benefits from the usual controls: a vehicle-only condition prepared with the identical diluent, a concentration series rather than a single level, replicates on separate days, and a reference compound with a known response run in parallel. A four-way side-by-side is in the 2026 comparison article, and a Q&A format is in the cagrilintide research FAQ.
Frequently asked questions
What hormone is cagrilintide modeled on?
Amylin, a pancreatic hormone co-secreted with insulin. Cagrilintide is engineered for stability relative to the aggregation-prone native hormone.
What receptor system does it engage?
Amylin-receptor complexes formed by the calcitonin receptor with receptor-activity-modifying proteins (RAMPs), and the calcitonin receptor itself. Three RAMPs give the AMY1, AMY2 and AMY3 subtypes.
What does the fatty diacid do?
A C20 fatty diacid attached through a short linker promotes reversible binding to serum albumin, which slows clearance and extends exposure in animal models.
How large is the cagrilintide molecule?
Its theoretical average mass is approximately 4,409 Da, including the backbone, linker and fatty diacid. That is the reference value for mass-spectrometric identity testing.
Why was native amylin a poor laboratory reagent?
Human amylin forms amyloid fibrils in aqueous solution, which changes its effective concentration during an experiment. Stabilized analogs were developed largely to remove that variability.
Why is cagrilintide studied alongside GLP-1-pathway compounds?
Amylin and incretin signaling use different receptors and partly different neural circuits, so side-by-side and combination arms let researchers assign each readout to a pathway.
Does a prolonged signal always mean stronger receptor activation?
No. Sustained signaling can reflect slower clearance, persistent receptor occupancy or trafficking changes. Time-course design is needed to separate duration from intrinsic activity.
Which in-vitro assays are most common for amylin analogs?
cAMP accumulation in cells expressing defined calcitonin receptor and RAMP combinations, receptor-binding competition assays and thioflavin-T fibrillation assays.
How do I calculate the concentration of a reconstituted stock?
Divide the peptide mass in the vial by the diluent volume: 10 mg in 2 mL gives 5 mg/mL. The calculator returns the same result.
Why does mass spectrometry matter so much for this compound?
Because it confirms that the acyl chain and the disulfide are both present. Acylation and oxidation each change mass and retention, so purity alone does not prove the intended molecule.
Research use only. For laboratory research use only; not for human consumption. Nothing in this guide is usage guidance; concentration arithmetic describes laboratory stock preparation only.
References
- V8 Peptides. GLP-1, GIP and Glucagon Receptors Explained.